Want to see SE:VITR full AI Analyst Report?
VITR Stock Chart & Stats
kr133.00
-kr3.40(-1.91%)
At close: 4:00 PM EST
kr133.00
-kr3.40(-1.91%)
Day’s Range― - ―
52-Week Rangekr84.00 - kr152.50
Previous CloseN/A
Volume81.91K
Average Volume (3M)185.28K
Market Cap
kr15.50B
Enterprise Valuekr13.62B
Total Cash (Recent Filing)kr860.00M
Total Debt (Recent Filing)kr1.73B
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Jan 28, 2027EPS Estimate
1.13Next Dividend Ex-DateN/A
Dividend Yield0.96%
Share Statistics
EPS (TTM)-36.60
Shares Outstanding135,447,190
10 Day Avg. Volume220,495
30 Day Avg. Volume185,283
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.35
Price to Sales (P/S)5.39
P/FCF Ratio40.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.36
Revenue Forecast (FY)kr3.50B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelThe consumables model creates recurring demand tied to ongoing IVF procedures rather than relying only on infrequent equipment sales. This replenishment dynamic can support revenue visibility, strengthen clinic relationships, and provide a durable base for cross-selling instruments, software, and genetic-testing workflows.
Technology AdoptionStrong technology growth and rising EmbryoScope utilization indicate increasing adoption of Vitrolife’s laboratory solutions across regions. Higher installed-base penetration can deepen workflow integration, support follow-on demand, and expand the company’s strategic relevance to fertility clinics over multiple quarters.
Restructuring And Operating LeverageExecution of the restructuring program provides a pathway to improve the cost base while preserving added investment in sales, marketing, and IT. If the targeted savings become sustainable, they can strengthen operating leverage and help convert healthy gross margins into more resilient profitability.
Bears Say
Deep Profitability WeaknessLarge operating and net losses materially weaken earnings quality despite a healthy gross margin and relatively stable revenue. Continued losses can erode shareholder value, constrain internally funded investment, and make future performance more dependent on successful cost reduction and operational recovery.
China IVF WeaknessChina is the largest IVF market in APAC, so persistent cycle weakness creates a durable regional demand headwind for Vitrolife’s consumables, technologies, and related solutions. Demographic and affordability pressures may limit recovery even as state aid and reimbursement improve.
Cost And Cash-flow PressureInflationary materials and salary increases are reducing the immediate benefit of restructuring, while lower operating cash flow signals weaker cash conversion than the prior year. If these pressures persist, they could delay margin recovery and reduce flexibility to fund innovation and commercial expansion.
Vitrolife AB News
VITR FAQ
What was Vitrolife AB’s price range in the past 12 months?
Vitrolife AB lowest stock price was kr84.00 and its highest was kr152.50 in the past 12 months.
What is Vitrolife AB’s market cap?
Vitrolife AB’s market cap is kr15.50B.
When is Vitrolife AB’s upcoming earnings report date?
Vitrolife AB’s upcoming earnings report date is Jan 28, 2027 which is in 89 days.
How were Vitrolife AB’s earnings last quarter?
Vitrolife AB released its earnings results on Oct 22, 2026. The company reported kr0.922 earnings per share for the quarter, missing the consensus estimate of kr1.007 by -kr0.085.
Is Vitrolife AB overvalued?
According to Wall Street analysts Vitrolife AB’s price is currently Overvalued.
Does Vitrolife AB pay dividends?
Vitrolife AB pays a Annually dividend of kr1.1 which represents an annual dividend yield of 0.96%. See more information on Vitrolife AB dividends here
What is Vitrolife AB’s EPS estimate?
Vitrolife AB’s EPS estimate is 1.13.
How many shares outstanding does Vitrolife AB have?
Vitrolife AB has 135,447,190 shares outstanding.
What happened to Vitrolife AB’s price movement after its last earnings report?
Vitrolife AB reported an EPS of kr0.922 in its last earnings report, missing expectations of kr1.007. Following the earnings report the stock price went up 5.01%.
Which hedge fund is a major shareholder of Vitrolife AB?
Currently, no hedge funds are holding shares in SE:VITR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vitrolife AB
Vitrolife AB (publ) is a medical technology company specializing in the development, production, and global sale of products for assisted reproduction. Their comprehensive offering includes a variety of essential tools for fertility treatments, such as oocyte retrieval needles, sperm processing solutions, specialized in vitro fertilization media and oils, and micromanipulation pipettes. The company also provides general labware, incubators, cryopreservation products, and systems for preimplantation genetic testing. Furthermore, Vitrolife delivers advanced equipment, including the EmbryoScope and Primo Vision time-lapse systems, along with dedicated dishes and evaluation software for these platforms. Their technology portfolio extends to Octax laser and imaging systems, as well as environmental monitoring solutions like log and guard systems and wireless sensors. With its headquarters located in Gothenburg, Sweden, Vitrolife maintains a significant international presence, operating across Europe, the Middle East, and Africa; Asia; Japan and the Pacific; and both North and South America. Founded in 1994, the company was initially known as Scandinavian IVF Science before officially changing its name to Vitrolife AB (publ) in 1998.
Technical Analysis
Getinge
―
BICO Group AB Class B
―
CellaVision AB
―
Xvivo Perfusion AB
―
Bactiguard Holding AB
―